Journal List > Korean J Women Health Nurs > v.19(4) > 1089448

Jeong, Nho, Kim, Lee, Yu, Lee, Sim, and Lee: Characteristics and Quality of Life in Gynecologic Cancer Patients with Chemotherapy-induced Peripheral Neuropathy

Abstract

Purpose

The purpose of this study was to identify chemotherapy induced peripheral neuropathy, quality of life of patients with gynecologic cancer.

Methods

This was a cross-sectional survey design. We collected 130 patients with gynecologic cancer. They complete a self reported questionnaire including items related neuropathy and quality of life (FACT-GOG/Ntx subscale, FACT-G scale).

Results

The neuropathy score was 14.3±7.9. The quality of life score was 64.8±16.4. The neuropathy induced significant difference according to diabetic status, difficulties in performing household chores and willing to discontinuity of chemotherapy. And duration of cancer diagnosis, neuropathy, number of total chemo agent associated with quality of life. There was a negative correlation between number of total chemo agent and quality of life. Neuropathy independently affected quality of life.

Conclusion

Chemotherapy induced peripheral neuropathy of patients with gynecologic cancer adversely affected women's quality of life and activities of daily living. To improve patient's quality of life, it is important that accurate assess and appropriately manage neuropathy in patients with gynecologic cancer.

Figures and Tables

Table 1
Neuropathy and Quality of Life by General Characteristics (N=130)
kjwhn-19-201-i001

FACT/GOG-Ntx subscale=functional assessment of cancer therapy/gynecologic oncology group neurotoxicity subscale; FACT-G=functional assessment of cancer therapy-general.

Scheffé test.

Table 2
Neuropathy and Quality of Life by Characteristics related to Neuropathy (N=130)
kjwhn-19-201-i002

FACT/GOG-Ntx subscale=functional assessment of cancer therapy/gynecologic oncology group neurotoxicity subscale; FACT-G=functional assessment of cancer therapy-general.

Scheffé test.

Table 3
Correlation of Major Variables with Neuropathy, Quality of Life (N=130)
kjwhn-19-201-i003

FACT/GOG-Ntx subscale=functional assessment of cancer therapy/gynecologic oncology group neurotoxicity subscale; FACT-G=functional assessment of cancer therapy-general.

Table 4
Score of Neuropathy and Quality of Life (N=130)
kjwhn-19-201-i004

FACT/GOG-Ntx subscale=functional assessment of cancer therapy/gynecologic oncology group neurotoxicity subscale; FACT-G=functional assessment of cancer therapy-generall; PWB=physical well-being; SWB=social/family well-being; EWB=emotional well-being; FWB=functional well-being.

Table 5
Factors affecting Quality of Life (N=130)
kjwhn-19-201-i005

References

1. Bakitas MA. Background noise: The experience of chemotherapy-induced peripheral neuropathy. Nurs Res. 2007; 56:323–331. http://dx.doi.org/10.1097/01.nnr.0000289503.22414.79.
2. Bartlett JE, Kotrlik JW, Higgins CC. Organizational research: Determining appropriate sample size in survey research. Inf Technol Learn Perform J. 2001; 19:43–50.
3. Berek JS. Berek & Novak's Gynecology. 14ed. Philadelphia: Lippincott;2007.
4. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, et al. Psychometric evaluation of functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity(FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003; 13:741–748.
5. Cella D. Manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Evanston: IL:Center on outcomes research and education (CORE);Evanston Northwestern Healthcare and Northwestern University;1997.
6. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy induced peripheral neuropathy. Semin Oncol. 2006; 33:15–49.
7. Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol. 2009; 145:3–14. http://dx.doi.org/10.1111/j.1365-2141.2008.07558.x.
crossref
8. Kim HM. Symptoms and relief therapy related to chemotherapy induced peripheral neuropathy in patients with cancer. Daegu: Keimyoung University;2012. Unpublished master's thesis.
9. Kim JH, Choi KS, Kim TW, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs. 2011; 11:254–262. http://dx.doi.org/10.5388/jkon.2011.11.3.254.
crossref
10. Kiser DW, Greer TB, Wilmoth MC, Dmochowski J, Naumann RW. Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments. Oncol Nurs Forum. 2010; 37:758–764. http://dx.doi.org/10.1188/10.ONF.758-764.
crossref
11. Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwang MS. Characteristics and quality of life in patients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs. 2010; 10:231–239.
crossref
12. Long HJ, Monk BJ, Huang HQ, Grendys EC, McMeekin DS, Sorosky J, et al. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A gynecologic oncology group study. Gynecol Oncol. 2006; 100:537–543.
crossref
13. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006; 7:797–809.
crossref
14. Pan Y, Kao MS. Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy. Int J Gynecol Cancer. 2007; 17:394–397. http://dx.doi.org/10.1111/j.1525-1438.2006.00766.x.
crossref
15. Park AR, Kim SJ, Bang JS, La HO. Oxaliplatin-induced peripheral neuropathy in patients with advanced or metastatic gastric cancer. Korean J Clin Pharm. 2009; 19:18–22.
16. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, cross-over trial. Cancer. 2007; 110:2110–2118. http://dx.doi.org/10.1002/cncr.23008.
17. Smith EL, Whedon MB, Bookbinder M. Quality improvement of painful peripheral neuropathy. Semin Oncol Nurs. 2002; 18:36–43.
crossref
18. Smith EM, Beck SL, Cohen J. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008; 35:96–102. http://dx.doi.org/10.1188/08.ONF.96-102 .
crossref
19. Cancer occurrence ratio in Korea women. Statistics Korea;2010. Retrieved July, 15, 2013. from http://kosis.kr/wnsearch/totalSearch.jsp.
20. Sweeney CW. Understanding peripheral neuropathy in patients with cancer: Background and patients assessment. Clin J Oncol Nurs. 2002; 6:163–166.
21. Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2010; 14:E22–E28. http://dx.doi.org/10.1188/10.CJON.E22-E28.
crossref
22. Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs. 2011; 15:182–188. http://dx.doi.org/10.1188/11.CJON.182-188.
crossref
23. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complication of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs. 2003; 63:1549–1563.
24. Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advancedovarian cancer patients. Ann Oncol. 2006; 17:429–436. http://dx.doi.org/10.1093/annonc/mdj097.
25. Wickham R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007; 11:361–376.
crossref
26. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer. 2008; 44:1507–1515. http://dx.doi.org/10.1016/j.ejca.2008.04.018.
crossref
27. Yarbro CH, Frogge MH, Goodman M. Cancer symptom management. 3rd ed. Boston: Jones and Bartlett;2004.
TOOLS
Similar articles